Septic shock: New pharmacotherapy options or better trial design?

Expert Opinion on Pharmacotherapy

Volumn 14, Issue 5, 2013, Pages 561-570

  Vincent, Jean Louis ^a   Van Nuffelen, Marc ^a  

^a ERASME HOSPITAL   (Belgium)

Author keywords

Activated protein C; Corticosteroids; Endotoxin; Immunomodulation; Nitric oxide; Sepsis; Septic shock; Tumor necrosis factor

Indexed keywords

546C 88; ANTITHROMBIN III; BT 086; DEXAMETHASONE; DROTRECOGIN; ERITORAN; FLUDROCORTISONE; GINKGOLIDE B; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEPARIN; HORMONE RECEPTOR STIMULATING AGENT; HUMAN GROWTH HORMONE; HYDROCORTISONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IBUPROFEN; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY; NORADRENALIN; PLACEBO; POLYMYXIN; PYRIDOXYLPOLYHEMOGLOBIN; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RECOMBINANT THROMBOMODULIN; RECOMBINANT TISSUE FACTOR PATHWAY INHIBITOR; ROSUVASTATIN; SIMVASTATIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASOPRESSIN; VASOPRESSIN V1A RECEPTOR AGONIST;

ACUTE LUNG INJURY; ANTICOAGULATION; BACTERIAL INFECTION; BLOOD CLOTTING; BOLUS INJECTION; BURN; COMMUNITY ACQUIRED PNEUMONIA; CORTICOSTEROID THERAPY; CRITICALLY ILL PATIENT; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG EFFICACY; DRUG SAFETY; FEVER; GRAM NEGATIVE INFECTION; GRAM NEGATIVE SEPSIS; HEMOPERFUSION; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOSTIMULATION; LOW DRUG DOSE; MONOCYTE; MORTALITY; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEPSIS; SEPTIC SHOCK; SHOCK; TREATMENT DURATION;

ANIMALS; CLINICAL TRIALS AS TOPIC; DRUG DISCOVERY; HUMANS; IMMUNOLOGIC FACTORS; RESEARCH DESIGN; SHOCK, SEPTIC; TREATMENT OUTCOME;

EID: 84874989226     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2013.777429     Document Type: Review

References (75)

1. Czura CJ. "Merinoff symposium 2010: sepsis"-speaking with one voice. Mol Med 2011;17:2-3
2. Vincent JL, Opal S, Marshall JC, et al. Sepsis definitions: time for change. Lancet 2013;In press
3. Vincent JL, Moreno R. Clinical review: scoring systems in the critically ill. Crit Care 2010;14:207
4. Werdan K, Pilz G, Bujdoso O, et al. Score-based immunoglobulin G therapy of patients with sepsis: the SBITS study. Crit Care Med 2007;35:2693-701
5. Kreymann KG, de Heer G, Nierhaus A, et al. Use of polyclonal immunoglobulins as adjunctive therapy for sepsis or septic shock. Crit Care Med 2007;35:2677-85
6. Laupland KB, Kirkpatrick AW, Delaney A. Polyclonal intravenous immunoglobulin for the treatment of severe sepsis and septic shock in critically ill adults: a systematic review and meta-analysis. Crit Care Med 2007;35:2686-92
7. Turgeon AF, Hutton B, Fergusson DA, et al. Meta-analysis: intravenous immunoglobulin in critically ill adult patients with sepsis. Ann Intern Med 2007;146:193-203
8. Ziegler EJ, Fisher CJ Jr, Sprung CL, et al. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group. N Engl J Med 1991;324:429-36
9. McCloskey RV, Straube RC, Sanders C, et al. Treatment of septic shock with human monoclonal antibody HA-1A. A randomized, double-blind, placebo-controlled trial. CHESS Trial Study Group. Ann Intern Med 1994;121:1-5
10. Greenman RL, Schein RM, Martin MA, et al. A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. The XOMA Sepsis Study Group. JAMA 1991;266:1097-102
11. Vincent JL, Sakr Y, Sprung CL, et al. Sepsis in European intensive care units: results of the SOAP study. Crit Care Med 2006;34:344-53
12. Dellinger RP, Tomayko JF, Angus DC, et al. Efficacy and safety of a phospholipid emulsion (GR270773) in Gram-negative severe sepsis: results of a phase II multicenter, randomized, placebo-controlled, dose-finding clinical trial. Crit Care Med 2009;37:2929-38
13. Vincent JL, Laterre PF, Cohen J, et al. A pilot-controlled study of a polymyxin B-immobilized hemoperfusion cartridge in patients with severe sepsis secondary to intra-abdominal infection. Shock 2005;23:400-5
14. Cruz DN, Antonelli M, Fumagalli R, et al. Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial. JAMA 2009;301:2445-52
15. Vincent JL. Sepsis: clearing the blood in sepsis. Nat Rev Nephrol 2009;5:559-60
16. Abraham E, Anzueto A, Gutierrez G, et al. Double-blind randomised controlled trial of monoclonal antibody to human tumor necrosis factor in treatment of septic shock. Lancet 1998;351:929-33
17. Fisher CJ, Dhainaut JF, Opal SM, et al. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. JAMA 1994;271:1836-43
18. Opal SM, Fisher CJ Jr, Dhainaut JF, et al. Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. Crit Care Med 1997;25:1115-24
19. Abraham E, Laterre PF, Garbino J, et al. Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: a randomized, double-blind, placebo-controlled, multicenter phase III trial with 1,342 patients. Crit Care Med 2001;29:503-10
20. Sorensen J, Kald B, Tagesson C, et al. Platelet-activating factor and phospholipase A2 in patients with septic shock and trauma. Intensive Care Med 1994;20:555-61
21. Dhainaut JF, Tenaillon A, Le Tulzo Y, et al. Platelet-activating factor receptor antagonist BN 52021 in the treatment of severe sepsis: a randomized, double-blind, placebo-controlled, multicenter clinical trial. BN 52021 Sepsis Study Group. Crit Care Med 1994;22:1720-8
22. Dhainaut JF, Tenaillon A, Hemmer M, et al. Confirmatory platelet-activating factor receptor antagonist trial in patients with severe gram-negative bacterial sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. BN 52021 sepsis investigator group. Crit Care Med 1998;26:1963-71
23. Opal S, Laterre PF, Abraham E, et al. Recombinant human platelet-activating factor acetylhydrolase for treatment of severe sepsis: results of a phase III, multicenter, randomized, double-blind, placebo-controlled, clinical trial. Crit Care Med 2004;32:332-41
24. Sprung CL, Caralis PV, Marcial EH, et al. The effects of high-dose corticosteroids in patients with septic shock. N Engl J Med 1984;311:1137-43
25. The Veterans Administration Systemic Sepsis Cooperative Study Group. effect of high-dose glucocorticoid therapy on mortality in patients with clinical signs of systemic sepsis. N Engl J Med 1987;317:659-65
26. Annane D, Sebille V, Troche G, et al. A 3-level prognostic classification in septic shock based on cortisol levels and cortisol response to corticotropin. JAMA 2000;283:1038-45
27. Annane D, Sebille V, Charpentier C, et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 2002;288:862-71
28. Vincent JL. Steroids in Sepsis: another swing of the pendulum in our clinical trials. Crit Care 2008;12:141
29. Sprung CL, Annane D, Keh D, et al. Hydrocortisone therapy for patients with septic shock. N Engl J Med 2008;358:111-24
30. Schortgen F, Clabault K, Katsahian S, et al. Fever control using external cooling in septic shock: a randomized controlled trial. Am J Respir Crit Care Med 2012;185:1088-95
31. Bernard GR, Wheeler AP, Russell JA, et al. The effects of ibuprofen on the physiology and survival of patients with sepsis. The Ibuprofen in Sepsis Study Group. N Engl J Med 1997;336:912-18
32. Warren BL, Eid A, Singer P, et al. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA 2001;286:1869-78
33. Hoffmann JN, Wiedermann CJ, Juers M, et al. Benefit/risk profile of high-dose antithrombin in patients with severe sepsis treated with and without concomitant heparin. Thromb Haemost 2006;95:850-6
34. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344:699-709
35. Vincent JL, Bernard GR, Beale R, et al. Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE. Crit Care Med 2005;33:2266-77
36. Abraham E, Laterre PF, Garg R, et al. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med 2005;353:1332-41
37. Nadel S, Goldstein B, Williams MD, et al. Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial. Lancet 2007;369:836-43
38. Angus DC. Drotrecogin alfa (activated). a sad final fizzle to a roller-coaster party. Crit Care 2012;16:107
39. Kalil AC, LaRosa SP. Effectiveness and safety of drotrecogin alfa (activated) for severe sepsis: a meta-analysis and metaregression. Lancet Infect Dis 2012;12:678-86.
40. Saito H, Maruyama I, Shimazaki S, et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART- 123) in disseminated intravascular coagulation: results of a phase III, randomized, double-blind clinical trial. J Thromb Haemost 2007;5:31-41
41. Abraham E, Reinhart K, Svoboda P, et al. Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: a multicenter, randomized, placebo-controlled, single-blind, dose escalation study. Crit Care Med 2001;29:2081-9
42. Abraham E, Reinhart K, Opal S, et al. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA 2003;290:238-47
43. Laterre PF, Opal SM, Abraham E, et al. A clinical evaluation committee assessment of recombinant human tissue factor pathway inhibitor (tifacogin) in patients with severe community-acquired pneumonia. Crit Care 2009;13:R36
44. Wunderink RG, Laterre PF, Francois B, et al. Recombinant tissue factor pathway inhibitor in severe community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med 2011;183:1561-8
45. Cornet AD, Smit EG, Beishuizen A, et al. The role of heparin and allied compounds in the treatment of sepsis. Thromb Haemost 2007;98:579-86
46. Agarwal R, Gupta D. Anticoagulation in sepsis: is low-dose heparin as effective as activated protein C? Intensive Care Med 2005;31:1297-8
47. Jaimes F, de la Rosa G, Morales C, et al. Unfractioned heparin for treatment of sepsis: a randomized clinical trial (The HETRASE Study). Crit Care Med 2009;37:1185-96
48. Novack V, Terblanche M, Almog Y. Do statins have a role in preventing or treating sepsis? Crit Care 2006;10:113
49. Kouroumichakis I, Papanas N, Proikaki S, et al. Statins in prevention and treatment of severe sepsis and septic shock. Eur J Intern Med 2011;22:125-33
50. Kopterides P, Falagas ME. Statins for sepsis: a critical and updated review. Clin Microbiol Infect 2009;15:325-34
51. Dobesh PP, Klepser DG, McGuire TR, et al. Reduction in mortality associated with statin therapy in patients with severe sepsis. Pharmacotherapy 2009;29:621-30
52. Donnino MW, Cocchi MN, Howell M, et al. Statin therapy is associated with decreased mortality in patients with infection. Acad Emerg Med 2009;16:230-4
53. Majumdar SR, McAlister FA, Eurich DT, et al. Statins and outcomes in patients admitted to hospital with community acquired pneumonia: population based prospective cohort study. BMJ 2006;333:999
54. Novack V, Eisinger M, Frenkel A, et al. The effects of statin therapy on inflammatory cytokines in patients with bacterial infections: a randomized double-blind placebo controlled clinical trial. Intensive Care Med 2009;35:1255-60
55. Kruger PS, Harward ML, Jones MA, et al. Continuation of statin therapy in patients with presumed infection: a randomized controlled trial. Am J Respir Crit Care Med 2011;183:774-81
56. Takala J, Ruokonen E, Webster NR, et al. Increased mortality associated with growth hormone treatment in critically ill adults. N Engl J Med 1999;341:785-92
57. Lopez A, Lorente JA, Steingrub J, et al. Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: effect on survival in patients with septic shock. Crit Care Med 2004;32:21-30
58. Russell JA, Walley KR, Singer J, et al. Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med 2008;358:877-87
59. Rehberg S, Ertmer C, Vincent JL, et al. Role of selective V1a receptor agonism in ovine septic shock. Crit Care Med 2011;39:119-25
60. Volk HD, Reinke P, Krausch D, et al. Monocyte deactivation-rationale for a new therapeutic strategy in sepsis. Intensive Care Med 1996;22(Suppl 4):S474-81
61. Docke WD, Randow F, Syrbe U, et al. Monocyte deactivation in septic patients: restoration by IFN-gamma treatment. Nat Med 1997;3:678-81
62. Wasserman D, Ioannovich JD, Hinzmann RD, et al. Interferon-gamma in the prevention of severe burn-related infections: a European phase III multicenter trial. The Severe Burns Study Group. Crit Care Med 1998;26:434-9
63. Eichacker PQ, Waisman Y, Natanson C, et al. Cardiopulmonary effects of granulocyte colony stimulating factor in a canine model of bacterial peritonitis. J Appl Physiol 1994;77:2366-73
64. O'Reilly M, Silver GM, Greenhalgh DG, et al. Treatment of intra-abdominal infection with granulocyte colony-stimulating factor. J Trauma 1992;33:679-82
65. Carr R, Brocklehurst P, Dore CJ, et al. Granulocyte-macrophage colony stimulating factor administered as prophylaxis for reduction of sepsis in extremely preterm, small for gestational age neonates (the PROGRAMS trial): a single-blind, multicentre, randomised controlled trial. Lancet 2009;373:226-33
66. Meisel C, Schefold JC, Pschowski R, et al. Granulocyte-macrophage colony-stimulating factor to reverse sepsis-associated immunosuppression: a double-blind, randomized, placebo-controlled multicenter trial. Am J Respir Crit Care Med 2009;180:640-8
67. Bo L, Wang F, Zhu J, et al. Granulocyte-colony stimulating factor (G-CSF) and granulocyte-macrophage colony stimulating factor (GM-CSF) for sepsis: a meta-analysis. Crit Care 2011;15:R58
68. Warren HS, Amato SF, Fitting C, et al. Assessment of ability of murine and human anti-lipid A monoclonal antibodies to bind and neutralize lipopolysaccharide. J Exp Med 1993;177:89-97
69. Vincent JL. Dear SIRS, I'm sorry to say that I don't like you. Crit Care Med 1997;25:372-4
70. Levy MM, Fink MP, Marshall JC, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International sepsis definitions conference. Crit Care Med 2003;31:1250-6
71. Baudo F, Caimi TM, de CF, et al. Antithrombin III (ATIII) replacement therapy in patients with sepsis and/or postsurgical complications: a controlled double-blind, randomized, multicenter study. Intensive Care Med 1998;24:336-42
72. Kienast J, Juers M, Wiedermann CJ, et al. Treatment effects of high-dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. J Thromb Haemost 2006;4:90-7
73. Rivers E, Nguyen B, Havstad S, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001;345:1368-77
74. Kumar A, Roberts D, Wood KE, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006;34:1589-96
75. Pickkers P, Heemskerk S, Schouten J, et al. Alkaline phosphatase for treatment of sepsis-induced acute kidney injury: a prospective randomized double-blind placebo-controlled trial. Crit Care 2012;16:R14